Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma

Minerva Gastroenterologica e Dietologica

Volumn 55, Issue 2, 2009, Pages 123-138

  Hussain, K ^a   El Serag, H B ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

Author keywords

Carcinoma, hepatocellular; Fatty liver; Hepatitis B; Obesity

Indexed keywords

AFLATOXIN B1; ALCOHOL; ALPHA FETOPROTEIN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; INTERFERON; MICROSPHERE Y 90; MITOMYCIN; OCTREOTIDE; PLACEBO; RADIOACTIVE MICROSPHERE; SORAFENIB; TAMOXIFEN; UNCLASSIFIED DRUG; BENZENESULFONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; TOPICAL ANTIINFECTIVE AGENT; TUMOR MARKER;

ABDOMINAL PAIN; ALCOHOL CONSUMPTION; ALGORITHM; ARTIFICIAL EMBOLISM; BONE MARROW DEPRESSION; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PALLIATIVE THERAPY; CANCER RISK; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHOLECYSTITIS; CIGARETTE SMOKING; COFFEE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; ECHOGRAPHY; ENVIRONMENTAL FACTOR; HEALTH CARE COST; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; ISCHEMIC CHOLECYSTITIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MINIMALLY INVASIVE PROCEDURE; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OVERALL SURVIVAL; PERCUTANEOUS ETHANOL INJECTION; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING TEST; SEX DIFFERENCE; THERAPY EFFECT; TOBACCO; TUMOR NECROSIS; VIRUS CARCINOGENESIS; VIRUS CARRIER; VOMITING; BLOOD; CATHETER ABLATION; DRUG COMBINATION; EVIDENCE BASED MEDICINE; HEALTH; HEALTH SURVEY; INCIDENCE; LIVER RESECTION; LIVER TUMOR; MASS SCREENING; METABOLISM; METHODOLOGY; PATHOLOGY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

ALGORITHMS; ALPHA-FETOPROTEINS; ANTI-INFECTIVE AGENTS, LOCAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; DRUG THERAPY, COMBINATION; EMBOLIZATION, THERAPEUTIC; ETHANOL; EVIDENCE-BASED MEDICINE; HEPATECTOMY; HUMANS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MASS SCREENING; NEOPLASM STAGING; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; PYRIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE; TEXAS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH;

EID: 68149141442     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (118)

1. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF, Jr. International trends and patterns of primary liver cancer. Int J Cancer 2001;94:290-6. (Pubitemid 32911426)
2. Parkin DM WSFJRLYJe. Cancer Incidence in Five Continents, Vol. VIII. Lyon: IARCPress. IARC Scientific Publications No 155 Lyon: IARC Press 2002.
3. Yu S. Primary prevention of hepatocellular carcinoma. J Gastoenterol Hepatol 1995;10:674-82.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50. (Pubitemid 29114292)
5. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127(5 Suppl 1):S27-S34. (Pubitemid 39423367)
6. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res 1993;53:790-4.
7. Yu MW, Yang YC, Yang SY, Cheng SW, Liaw YF, Lin SM et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst 2001;93:1644-51.
8. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002;62(Suppl 1):8-17. (Pubitemid 34702014)
9. Armstrong GL, Alter MJ, McQuillan GM, Margolis HS. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777-82. (Pubitemid 30118650)
10. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000;90:1562-9.
11. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and dinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J Clin Microbiol 2002;40:1207-9.
12. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31. (Pubitemid 34132050)
13. Cramp ME. HBV + HCV = HCC? Gut 1999;45:168-9. (Pubitemid 29333762)
14. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepato-cellular Carcinoma Study Group. Lancet 1998;351:1535-9.
15. Bruno S, Battezzati PM, Bellati G, Manzin A, Maggioni M, Crosignani A et al. Long-term beneficial effects in sustained responders to interferon-alfa therapy for chronic hepatitis C. J Hepatol 2001;34:748-55. (Pubitemid 32488791)
16. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-30. (Pubitemid 29168746)
17. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99. (Pubitemid 28337250)
18. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurler D et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-95. (Pubitemid 28549142)
19. Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653-9. (Pubitemid 29151907)
20. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998;27:1435-40. (Pubitemid 28227875)
21. Valla DC, Chevallier M, Marcellin P, Payen JL, Trepo C, Fonck M et al. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology 1999;29:1870-5. (Pubitemid 29247063)
22. Garner RC, Miller EC, Miller JA. Liver microsomal metabolism of aflatoxin B 1 to a reactive derivative toxic to Salmonella typhimurium TA 1530. Cancer Res 1972;32:2058-66.
23. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-31. (Pubitemid 21912246)
24. Turner PC, Sylla A, Diallo MS, Castegnaro JJ, Hall AJ, Wild CP. The role of aflatoxins and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. J Gastroenterol Hepatol 2002;17(Suppl):S441-S8.
25. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-54.
26. Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. (Pubitemid 34747534)
27. Regimbeau JM, Colombat M, Mognol P, Durand F, Abdalla E, Degott C et al. Obesity and diabetes as a risk factor for hepatocellular carcinoma. Liver Transpl 2004; 10(2 Suppl 1):S69-S73. (Pubitemid 38240104)
28. Adams LA, Lymp JF, St SJ, Sanderson SO, Lindor KD, Feldstein A et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21. (Pubitemid 41002048)
29. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
30. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30A:344-50. (Pubitemid 24152476)
31. Wolk A, Gridley G, Svensson M, Nyren O, McLaughlin JK, Fraumeni JF et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21. (Pubitemid 32125897)
32. Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996;88:1472-7. (Pubitemid 26340049)
33. El Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8. (Pubitemid 38182303)
34. Wideroff L, Gridley G, Mellemkjaer L, Chow WH, Linet M, Keehn S et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-5. (Pubitemid 27418027)
35. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 2006;4:369-80. (Pubitemid 43343895)
36. Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La VC et al. Does coffee protect against hepatocellular carcinoma? Br J Cancer 2002;87:956-9. (Pubitemid 35305644)
37. Gelatti U, Covolo L, Franceschini M, Pirali F, Tagger A, Ribero ML et al. Coffee consumption reduces the risk of hepatocellular carcinoma independently of its aetiology: a case-control study. J Hepatol 2005;42:528-34. (Pubitemid 40342932)
38. Tanaka K, Hara M, Sakamoto T, Higaki Y, Mizuta T, Eguchi Y et al. Inverse association between coffee drinking and the risk of hepatocellular carcinoma: a case-control study in Japan. Cancer Sci 2007;98:214-8. (Pubitemid 44941873)
39. Ohfuji S, Fukushima W, Tanaka T, Habu D, Tamori A, Sakaguchi H et al. Coffee consumption and reduced risk of hepatocellular carcinoma among patients with chronic type C liver disease: A case-control study. Hepatol Res 2006;36:201-8. (Pubitemid 44575932)
40. Montella M, Polesel J, La VC, Dal ML, Crispo A, Crovatto M et al. Coffee and tea consumption and risk of hepatocellular carcinoma in Italy. Int J Cancer 2007;120:1555-9. (Pubitemid 46355393)
41. Shimazu T, Tsubono Y, Kuriyama S, Ohmori K, Koizumi Y, Nishino Y et al. Coffee consumption and the risk of primary liver cancer: pooled analysis of two prospective studies in Japan. Int J Cancer 2005;116:150-4. (Pubitemid 40827769)
42. Inoue M, Yoshimi I, Sobue T, Tsugane S. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst 2005;97:293-300. (Pubitemid 40310277)
43. Kurozawa Y, Ogimoto I, Shibata A, Nose T, Yoshimura T, Suzuki H et al. Coffee and risk of death from hepatocellular carcinoma in a large cohort study in Japan. Br J Cancer 2005;93:607-10. (Pubitemid 43080007)
44. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36. (Pubitemid 43112690)
45. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-22.
46. Chen JG, Parkin DM, Chen QG, Lu JH, Shen QJ, Zhang BC et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. J Med Screen 2003;10:204-9. (Pubitemid 38091209)
47. Wong LL, Limm WM, Severino R, Wong LM. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 2000;6:320-5. (Pubitemid 30317228)
48. Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002,97:734-4.
49. Zhang B, Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999;6:108-10. (Pubitemid 29320849)
50. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9. (Pubitemid 32141852)
51. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27:273-8. (Pubitemid 28041564)
52. Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001;20:99-104.
53. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-5. (Pubitemid 32328514)
54. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:432-8.
55. Trevisani F, D'Intino PE, Caraceni P, Pizzo M, Stefanini GF, Mazziotti A et al. Etiologic factors and clinical presentation of hepatocellular carcinoma. Differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995;75:2220-32.
56. Bayati N, Silverman AL, Gordon SC. Serum alpha-feto-protein levels and liver histology in patients with chronic hepatitis C. Am J Gastroenterol 1998;93:2452-6. (Pubitemid 29018554)
57. Franca AV, Elias JJ, Lima BL, Martinelli AL, Carrilho FJ. Diagnosis, staging and treatment of hepatocellular carcinoma. Braz J Med Biol Res 2004;37:1689-705. (Pubitemid 39555461)
58. Chen TH, Chen CJ, Yen MF, Lu SN, Sun CA, Huang GT et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002,98:257-61. (Pubitemid 34150810)
59. Patel D, Terrault NA, Yao FY, Bass NM, Ladabaum U. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2005;3:75-84. (Pubitemid 40092947)
60. Saab S, Ly D, Nieto J, Kanwal F, Lu D, Raman S et al. Hepatocellular carcinoma screening in patients waiting for liver transplantation: a decision analytic model. Liver Transpl 2003,9:672-81. (Pubitemid 36874452)
61. Choi D, Kim SH, Lim JH, Cho JM, Lee WJ, Lee SJ et al. Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr 2001;25:777-85. (Pubitemid 32861704)
62. Arguedas MR, Chen VK, Eloubeidi MA, Fallon MB. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003;98:679-90. (Pubitemid 36348544)
63. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transpl 2005;11:281-9. (Pubitemid 40458400)
64. Burrel M, Llovet JM, Ayuso C, Iglesias C, Sala M, Miquel R et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an expiant correlation. Hepatology 2003;38:1034-42. (Pubitemid 37221687)
65. de Ledinghen V, Laharie D, Lecesne R, Le BB, Winnock M, Bernard PH et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002;14:159-65. (Pubitemid 34163995)
66. Rode A, Bancel B, Douek P, Chevallier M, Vilgrain V, Picaud G et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 2001;25:327-36. (Pubitemid 32440782)
67. Ebara M, Ohto M, Watanabe Y, Kimura K, Saisho H, Tsuchiya Y et al. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology 1986;159:371-7.
68. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-30. (Pubitemid 32844200)
69. Byrnes V, Shi H, Kiryu S, Rofsky NM, Afdhal NH. The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver. Am J Gastroenterol 2007;102:1654-9. (Pubitemid 47206703)
70. Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, Terris B et al. Assessment of the benefits and risks of percutaneous biopsy before surgical resection of hepatocellular carcinoma. J Hepatol 2001;35:254-8. (Pubitemid 32803481)
71. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-38.
72. Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-16. (Pubitemid 40462931)
73. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. Cancer 1990;65:1864-6. (Pubitemid 20116663)
74. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998;352:17-20.
75. Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995;109:917-22.
76. Farinati F. Tamoxifen treatment in hepatocellular carcinoma. Gastroenterology 1996;111:272-4.
77. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-91. (Pubitemid 34977180)
78. Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-8. (Pubitemid 30033689)
79. Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-7. (Pubitemid 28135581)
80. El-Serag HB, Marrero JA, Rudolph L, Reddy KR. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 2008;134:1752-63. (Pubitemid 351615415)
81. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999 Dec;30(6):1434-1440.
82. Zhou XD, Tang ZY, Yang BH, Lin ZY, Ma ZC, Ye SL, et al. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma. Cancer 2001;91:1479-86.
83. Shi M, Guo RP, Lin XJ, Zhang YQ, Chen MS, Zhang CQ et al. Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007;245:36-43. (Pubitemid 46035433)
84. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9. (Pubitemid 26079803)
85. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311-22.
86. Jonas S, Bechstein WO, Steinmuller T, Herrmann M, Radke C, Berg T et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-6. (Pubitemid 32378206)
87. Leung JY, Zhu AX, Gordon FD, Pratt DS, Mithoefer A, Garrigan K et al. Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study. Liver Transpl 2004;10:1343-54. (Pubitemid 39530049)
88. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587-96. (Pubitemid 47561609)
89. Duffy JP, Vardanian A, Benjamin E, Watson M, Farmer DG, Ghobrial RM et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007;246:502-9. (Pubitemid 47312148)
90. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S268-S76.
91. Yao FY, Kerlan RK, Jr., Hirose R, Davern TJ, III, Bass NM, Feng S et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-27.
92. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006;25:3848-56. (Pubitemid 43980480)
93. Ringe B, Pichlmayr R, Wittekind C, Tusch G. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991 Mar;15(2):270-285.
94. Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M, Takayama T, et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 1996 May 1;77:1792-6. (Pubitemid 26125178)
95. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer 1992;69:925-9.
96. Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353-7.
97. Livraghi T, Bolondi L, Buscarini L, Cottone M, Mazziotti A, Morabito A et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Italian Cooperative HCC Study Group. J Hepatol 1995;22:522-6.
98. Yamamoto J, Okada S, Shimada K, Okusaka T, Yamasaki S, Ueno H et al. Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001;34(4 Pt 1):707-13. (Pubitemid 32927994)
99. Ryu M, Shimamura Y, Kinoshita T, Konishi M, Kawano N, Iwasaki M et al. Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study. Jpn J Clin Oncol 1997;27:251-7. (Pubitemid 127516775)
100. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-61. (Pubitemid 29124024)
101. Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-30. (Pubitemid 41002049)
102. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:1714-23.
103. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-40. (Pubitemid 36736097)
104. Teratani T, Yoshida H, Shiina S, Obi S, Sato S, Tateishi R et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 2006;43:1101-8. (Pubitemid 43724634)
105. Liu DQ, Lu MD, Tan JF, Wang Z, Zhou ZX. [Microwave coagulation at different temperatures for hepatocellular carcinoma management: efficacy evaluation by enzyme histochemical staining]. Nan Fang Yi Ke Da Xue Xue Bao 2006;26:1149-51.
106. Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, Zhang YQ et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8. (Pubitemid 43327762)
107. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9. (Pubitemid 34607087)
108. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl 1):S179-S88.
109. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42. (Pubitemid 36152543)
110. Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol 2006;17:1251-78. (Pubitemid 44259009)
111. Ibrahim SM, Lewandowski RJ, Sato KT, Gates VL, Kulik L, Mulcahy MF et al. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review. World J Gastroenterol 2008;14:1664-9. (Pubitemid 351493372)
112. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81. (Pubitemid 351171043)
113. Kulik LM, Atassi B, van HL, Souman T, Lewandowski RJ, Mulcahy MF et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006;94:572-86. (Pubitemid 44851918)
114. Llovet J, Ricci S, Mazzaferro V, Hilgard P, Raoul J, Zeuzem S et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). J Clin Onc 2007;25(18S (June 20 Supplement)):LBA1.
115. Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G et al. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 2005;23:6657-63. (Pubitemid 46190260)
116. El-Serag HB. Translational research: the study of community effectiveness in digestive and liver disorders. Gastroenterology 2007;132:8-10. (Pubitemid 46108760)
117. El-Serag HB, Siegel AB, Davila JA, Shaib YH, Cayton-Woody M, McBride R et al. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol 2006;44:158-66. (Pubitemid 41772530)
118. Siegel AB, McBride RB, El-Serag HB, Hershman DL, Brown RS, Jr., Renz JF et al. Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. Am J Gastroenterol 2008;103:120-7.